77.62
2.27%
1.72
Handel nachbörslich:
77.61
-0.01
-0.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$75.90
Offen:
$74.91
24-Stunden-Volumen:
530.73K
Relative Volume:
0.61
Marktkapitalisierung:
$12.31B
Einnahmen:
$1.16B
Nettoeinkommen (Verlust:
$168.11M
KGV:
51.07
EPS:
1.52
Netto-Cashflow:
$236.10M
1W Leistung:
+9.73%
1M Leistung:
+3.80%
6M Leistung:
+0.43%
1J Leistung:
+32.19%
Bio Techne Corp Stock (TECH) Company Profile
Firmenname
Bio Techne Corp
Sektor
Branche
Telefon
(612) 379-8854
Adresse
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
2024-02-08 | Eingeleitet | Scotiabank | Sector Outperform |
2024-02-02 | Herabstufung | Stifel | Buy → Hold |
2023-12-07 | Eingeleitet | UBS | Buy |
2023-08-28 | Eingeleitet | William Blair | Outperform |
2023-01-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
2022-12-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
2021-09-15 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
2021-03-08 | Hochstufung | Stephens | Equal-Weight → Overweight |
2021-02-23 | Hochstufung | Stifel | Hold → Buy |
2021-01-25 | Bestätigt | The Benchmark Company | Buy |
2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
2020-07-15 | Herabstufung | Stephens | Overweight → Equal-Weight |
2020-05-27 | Herabstufung | Stifel | Buy → Hold |
2020-05-14 | Eingeleitet | The Benchmark Company | Buy |
2020-01-08 | Fortgesetzt | Stephens | Overweight |
2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
2020-01-07 | Eingeleitet | Citigroup | Neutral |
2019-11-15 | Eingeleitet | Stifel | Buy |
2019-07-02 | Hochstufung | Janney | Neutral → Buy |
2019-01-14 | Hochstufung | Stephens | Equal-Weight → Overweight |
2018-10-31 | Herabstufung | Craig Hallum | Buy → Hold |
2018-10-17 | Eingeleitet | Goldman | Neutral |
2018-06-15 | Eingeleitet | Argus | Buy |
2017-07-13 | Eingeleitet | Wells Fargo | Market Perform |
2017-02-09 | Eingeleitet | Citigroup | Buy |
2017-01-18 | Eingeleitet | Deutsche Bank | Buy |
2016-11-10 | Fortgesetzt | Leerink Partners | Outperform |
2015-01-21 | Bestätigt | Robert W. Baird | Outperform |
2013-09-20 | Hochstufung | Robert W. Baird | Neutral → Outperform |
Alle ansehen
Bio Techne Corp Aktie (TECH) Neueste Nachrichten
Bio-Techne awards CFO restricted stock units for retention - Investing.com
LUNAPHORE COMET™ PLATFORM PAVES THE WAY FOR SPATIAL BIOLOGY ADOPTION IN CLINICAL RESEARCH - Yahoo Finance
Bio-Techne Co. (NASDAQ:TECH) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Bio-Techne Tops Q1 Earnings & Revenue Estimates, Stock Up in Premarket - MSN
Bio-Techne Corp (TECH)'s Winning Formula: Financial Metrics and Competitive Strengths - GuruFocus.com
New York State Common Retirement Fund Reduces Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne (NASDAQ:TECH) Raised to Buy at StockNews.com - Defense World
Bio-Techne (NASDAQ:TECH) Upgraded to Buy at StockNews.com - MarketBeat
9 Best Biotech Stocks Of November 2024 - Forbes
Bio-Techne Corporation (NASDAQ:TECH) Q1 2025 Earnings Call Transcript - Insider Monkey
TECH (Bio-Techne) Total Inventories : $185 Mil (As of Sep. 2024) - GuruFocus.com
Bio-Techne shares target raised, outperform on strong Q1 results By Investing.com - Investing.com Australia
Earnings call: Bio-Techne reports steady growth in Q1 FY2025 - Investing.com
Earnings call: Bio-Techne reports steady growth in Q1 FY2025 By Investing.com - Investing.com UK
Bio-Techne shares target raised, outperform on strong Q1 results - Investing.com India
Robert W. Baird Forecasts Strong Price Appreciation for Bio-Techne (NASDAQ:TECH) Stock - MarketBeat
Bio-Techne Corp (TECH) Q1 2025 Earnings Call Highlights: Navigat - GuruFocus.com
Bio-Techne Corp (TECH) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges in a ... - Yahoo Finance
Bio-Techne holds at $80 target with Overweight rating - Investing.com India
Bio-Techne holds at $80 target with Overweight rating By Investing.com - Investing.com South Africa
Objective long/short (TECH) Report - Stock Traders Daily
Bio-Techne Tops Profit Forecasts Thanks To Booming Diagnostics - Finimize
Bio-Techne Q1 25 Earnings Conference Call At 9:00 AM ET - Nasdaq
Bio-Techne beats quarterly profit estimates, driven by diagnostic unit growth; shares rise - Reuters
Bio-Techne Corp (TECH) Q1 FY2025 Earnings: Revenue Surpasses Est - GuruFocus.com
Bio-Techne earnings beat by $0.04, revenue topped estimates - Investing.com
BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2025 RESULTS - Yahoo Finance
Bio-Techne Co. (NASDAQ:TECH) Shares Sold by Creative Planning - MarketBeat
Sequoia Financial Advisors LLC Purchases Shares of 2,725 Bio-Techne Co. (NASDAQ:TECH) - Defense World
Global Exosome Market to Surge at a Tremendous CAGR of ~20% by 2030 | DelveInsight - GlobeNewswire Inc.
ScaleReady Announces a G-Rex® Grant has been awarded to Luminary Therapeutics - Yahoo Finance
Director Keegan Joseph D was granted 1,462 shares, increasing direct ownership by 12% to 13,771 units (SEC Form 4) - Quantisnow
IFM Investors Pty Ltd Boosts Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne Gears Up for Q1 Earnings Release: What's in the Cards? - MSN
Hahn Capital Management LLC Reduces Stock Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Raymond James & Associates Boosts Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne, Ex-Lead Scientist Settle Religious Bias Claim (1) - Bloomberg Law
Bio-Techne (TECH) Scheduled to Post Earnings on Wednesday - MarketBeat
Allspring Global Investments Holdings LLC Decreases Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
CRISPR-based Gene Editing Market Report 2024-2030, Featuring Revvity, Danaher, GenScript, Merck, Tocris Bioscience, OriGene Technologies, Bio-Rad Laboratories, Bio-Techne & New England Biolabs - Yahoo Finance
S&P 500 Futures Fall in Premarket Trading; Kenvue, Bio-Techne Lead - Barron's
When the Price of (TECH) Talks, People Listen - Stock Traders Daily
What You Need To Know Ahead Of Bio-Techne's Earnings Release - Barchart
What You Need to Know Ahead of Bio-Techne's Earnings Release - Inkl
Sanctuary Advisors LLC Takes Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Transferrin Monoclonal Antibody Market 2034 Insights with Key Innovations Analysis |MyBiosource, Inc., Bio-Techne, Abc – IndiaPolitics.com - IndiaPolitics.com
Anti-Olig2 Antibody Market Year 2034|Sino Biological, Inc., Boster Biological Technology, Bio-Techne, Thermo Fisher, CLO – IndiaPolitics.com - IndiaPolitics.com
CD30 (TNFRSF8) ELISA Kit Market Growth Report |Sino Biological, Inc., Bio-Techne, MyBiosource, Inc., Boster Biological T – IndiaPolitics.com - IndiaPolitics.com
An Analysis of Bio-Techne Corp (TECH)’s Potential Price Growth - Knox Daily
Investors in cash trouble should check out Bio-Techne Corp (TECH) - SETE News
Bio-Techne Co. (NASDAQ:TECH) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Finanzdaten der Bio Techne Corp-Aktie (TECH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bio Techne Corp-Aktie (TECH) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Kelderman Kim | Chief Executive Officer |
Aug 29 '24 |
Option Exercise |
66.97 |
1,492 |
99,919 |
41,434 |
Bohnen Shane | SVP - General Counsel |
Aug 15 '24 |
Option Exercise |
0.00 |
49 |
0 |
1,696 |
BAUMGARTNER ROBERT V | Director |
Aug 08 '24 |
Option Exercise |
22.95 |
16,000 |
367,200 |
59,401 |
BAUMGARTNER ROBERT V | Director |
Aug 08 '24 |
Sale |
72.10 |
16,000 |
1,153,664 |
43,401 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):